MTOR and hepatocellular carcinoma: Preclinical studies have demonstrated the effectiveness of the first generation of mTOR inhibitors rapamycin derivatives in HCC growth inhibition 44, 45, whereas they had very limited efficacy against advanced HCC in clinical trials 7, 46.